Chelation use and iron burden in North American and British thalassemia patients: A report from the thalassemia longitudinal cohort

Blood

Volumn 119, Issue 12, 2012, Pages 2746-2753

  Kwiatkowski, Janet L ^a   Kim, Hae Young ^b   Thompson, Alexis A ^c   Quinn, Charles T ^d   Mueller, Brigitta U ^e   Odame, Isaac ^f   Giardina, Patricia J ^g   Vichinsky, Elliott P ^h   Boudreaux, Jeanne M ⁱ   Cohen, Alan R ^a   Porter, John B ^j   Coates, Thomas ^k   Olivieri, Nancy F ^l   Neufeld, Ellis J ^m  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h CHILDREN S HOSPITAL OAKLAND   (United States)

ⁱ CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

^l TORONTO GENERAL HOSPITAL   (Canada)

^m BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; THALASSEMIA;

EID: 84863376394     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-344507     Document Type: Article

References (25)

1. Gabutti V, Piga A. Results of long-term iron chelating therapy. Acta Haematologica. 1996; 95(1):26-36. (Pubitemid 26071428)
2. Wolfe L, Oliveri N, Sallan D, et al. Prevention of cardiac disease by sucutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312(25):1600-1603. (Pubitemid 15062652)
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10): 1187-1193. (Pubitemid 39390442)
4. Modell B, Khan M, Darlison M. Survival in beta thalassaemia-major in the U. K.: data from the U.K. Thalassaemia Register. Lancet. 2000; 355(9220):2051-2052. (Pubitemid 30339248)
5. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331(9):574-578. (Pubitemid 24265699)
6. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997; 89(3):739-761. (Pubitemid 27121266)
7. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861. (Pubitemid 40070775)
8. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006;91(10):1388-1391. (Pubitemid 44569814)
9. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465. (Pubitemid 41129616)
10. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci. 2005;1054:373-378. (Pubitemid 43031044)
11. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
12. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7): 2973-2978.
13. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):42.
14. Lal A, Sweeters N, Herz M, et al. Safety of combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia [abstract]. Blood. 2009;114(22):2021.
15. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33-39. (Pubitemid 36791266)
16. Nielsen P, Engelhardt R, Grosse R, Janka G, Harmatz P, Fischer R. Italian Society of Hematology guidelines for thalassemia and noninvasive iron measurements. Haematologica. 2009;94(2): 294-295.
17. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
18. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol. 2008;80(2):168-176.
19. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980- 2004. Haematologica. 2006;91(9):1187-1192. (Pubitemid 44408428)
20. Thomas AS, Garbowski M, Ang AL, et al. A decade of follow-up of a thalassemia major (TM) cohort monitored by cardiac magnetic resonance imaging (CMR): significant reduction in patients with cardiac iron and in total mortality [abstract]. Blood. 2010;116(21):1011.
21. Ceci A, Mangiarini L, Felisi M, et al. The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients [published online ahead of print June 5, 2011]. Anemia. doi:10.1155/2011/435683.
22. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with betathalassemia. Clin Ther. 2007;29(5):909-917. (Pubitemid 47241173)
23. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in {beta}-thalassemia major. Blood. 2008; 111(2):583-587.
24. Alvarez O, Rodriguez-Cortes H, Robinson N, et al. Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy. J Pediatr Hematol Oncol. 2009;31(10): 739-744.
25. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179. (Pubitemid 33139463)